{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:38Z","timestamp":1783075958771,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sage Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40262-019-00801-0","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T07:30:31Z","timestamp":1563953431000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies"],"prefix":"10.1007","volume":"59","author":[{"given":"Ethan","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Nomikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Raines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul J.","family":"Sankoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Colquhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"issue":"18","key":"801_CR1","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","volume":"60","author":"G Martinez Botella","year":"2017","unstructured":"Martinez Botella G, Salituro FG, Harrison BL, et al. Neuroactive steroids. 2. 3\u03b1-hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-aminobutyric acid)A receptor. J Med Chem. 2017;60(18):7810\u20139.","journal-title":"J Med Chem."},{"issue":"7","key":"801_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.109.074120","volume":"51","author":"H Boecker","year":"2010","unstructured":"Boecker H, Weindl A, Brooks DJ, et al. GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. J Nucl Med. 2010;51(7):1030\u20135.","journal-title":"J Nucl Med"},{"issue":"6","key":"801_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jpsychires.2013.02.010","volume":"47","author":"KM Deligiannidis","year":"2013","unstructured":"Deligiannidis KM, Sikoglu EM, Shaffer SA, et al. GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: a preliminary study. J Psychiatr Res. 2013;47(6):816\u201328.","journal-title":"J Psychiatr Res"},{"key":"801_CR4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5334\/tohm.229","volume":"4","author":"A Gironell","year":"2014","unstructured":"Gironell A. The GABA hypothesis in essential tremor: lights and shadows. Tremor Other Hyperkinet Mov (N Y). 2014;4:254.","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"issue":"10","key":"801_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","volume":"81","author":"MS Lener","year":"2017","unstructured":"Lener MS, Niciu MJ, Ballard ED, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81(10):886\u201397.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"801_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuron.2008.06.019","volume":"59","author":"J Maguire","year":"2008","unstructured":"Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008;59(2):207\u201313.","journal-title":"Neuron"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/bs.apha.2014.11.003","volume":"73","author":"B Luscher","year":"2015","unstructured":"Luscher B, Fuchs T. GABAergic control of depression-related brain states. Adv Pharmacol. 2015;73:97\u2013144.","journal-title":"Adv Pharmacol"},{"issue":"10","key":"801_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0006-3223(02)01672-4","volume":"52","author":"JM Kent","year":"2002","unstructured":"Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002;52(10):1008\u201330.","journal-title":"Biol Psychiatry"},{"issue":"Suppl","key":"801_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nn944","volume":"5","author":"E Mignot","year":"2002","unstructured":"Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci. 2002;5(Suppl):1071\u20135.","journal-title":"Nat Neurosci"},{"issue":"161","key":"801_CR10","doi-asserted-by":"publisher","first-page":"161ra151","DOI":"10.1126\/scitranslmed.3004685","volume":"4","author":"DB Rye","year":"2012","unstructured":"Rye DB, Bliwise DL, Parker K, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med. 2012;4(161):161ra151.","journal-title":"Sci Transl Med."},{"key":"801_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cellsig.2018.07.003","volume":"50","author":"E Szodorai","year":"2018","unstructured":"Szodorai E, Bampali K, Romanov RA, et al. Diversity matters: combinatorial information coding by GABAA receptor subunits during spatial learning and its allosteric modulation. Cell Signal. 2018;50:142\u201359.","journal-title":"Cell Signal"},{"issue":"Suppl 3","key":"801_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1528-1157.2001.042suppl.3008.x","volume":"42","author":"DM Treiman","year":"2001","unstructured":"Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(Suppl 3):8\u201312.","journal-title":"Epilepsia"},{"issue":"41","key":"801_CR13","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","volume":"29","author":"D Belelli","year":"2009","unstructured":"Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW. Extrasynaptic GABAA receptors: form, pharmacology, and function. J Neurosci. 2009;29(41):12757\u201363.","journal-title":"J Neurosci"},{"issue":"1\u20133","key":"801_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0165-0173(01)00124-2","volume":"37","author":"JJ Lambert","year":"2001","unstructured":"Lambert JJ, Belelli D, Harney SC, Peters JA, Frenguelli BG. Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain Res Brain Res Rev. 2001;37(1\u20133):68\u201380.","journal-title":"Brain Res Brain Res Rev"},{"issue":"3","key":"801_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.pbb.2004.03.024","volume":"78","author":"CA Frye","year":"2004","unstructured":"Frye CA, Walf AA. Hippocampal 3alpha,5alpha-THP may alter depressive behavior of pregnant and lactating rats. Pharmacol Biochem Behav. 2004;78(3):531\u201340.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"801_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1017\/S1092852914000480","volume":"20","author":"CE Schiller","year":"2015","unstructured":"Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr. 2015;20(1):48\u201359.","journal-title":"CNS Spectr"},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","volume":"113","author":"C Schule","year":"2014","unstructured":"Schule C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol. 2014;113:79\u201387.","journal-title":"Prog Neurobiol"},{"issue":"10152","key":"801_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","volume":"392","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392(10152):1058\u201370.","journal-title":"Lancet"},{"issue":"10093","key":"801_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","volume":"390","author":"S Kanes","year":"2017","unstructured":"Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390(10093):480\u20139.","journal-title":"Lancet"},{"issue":"2","key":"801_CR20","doi-asserted-by":"publisher","first-page":"e2576","DOI":"10.1002\/hup.2576","volume":"32","author":"SJ Kanes","year":"2017","unstructured":"Kanes SJ, Colquhoun H, Doherty J, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol. 2017;32(2):e2576.","journal-title":"Hum Psychopharmacol"},{"key":"801_CR21","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2005."},{"issue":"4","key":"801_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","volume":"10","author":"E Hoddes","year":"1973","unstructured":"Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10(4):431\u20136.","journal-title":"Psychophysiology"},{"issue":"4","key":"801_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00004714-199008000-00003","volume":"10","author":"DA Chernik","year":"1990","unstructured":"Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer\u2019s Assessment of Alertness\/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990;10(4):244\u201351.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"801_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"801_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/A:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278\u201383.","journal-title":"Pharm Res"},{"issue":"4","key":"801_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","volume":"16","author":"B Luscher","year":"2011","unstructured":"Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383\u2013406.","journal-title":"Mol Psychiatry."},{"issue":"19","key":"801_CR27","doi-asserted-by":"publisher","first-page":"7132","DOI":"10.1073\/pnas.1403285111","volume":"111","author":"AM Abramian","year":"2014","unstructured":"Abramian AM, Comenencia-Ortiz E, Modgil A, et al. Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors. Proc Natl Acad Sci USA. 2014;111(19):7132\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"key":"801_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eplepsyres.2017.05.001","volume":"134","author":"RS Hammond","year":"2017","unstructured":"Hammond RS, Althaus AL, Ackley MA, et al. Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models. Epilepsy Res. 2017;134:16\u201325.","journal-title":"Epilepsy Res"},{"issue":"Pt A","key":"801_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.neuropharm.2016.10.010","volume":"113","author":"A Modgil","year":"2017","unstructured":"Modgil A, Parakala ML, Ackley MA, Doherty JJ, Moss SJ, Davies PA. Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism. Neuropharmacology. 2017;113(Pt A):314\u201322.","journal-title":"Neuropharmacology"},{"issue":"4","key":"801_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/ACO.0000000000000358","volume":"29","author":"B Antkowiak","year":"2016","unstructured":"Antkowiak B, Rudolph U. New insights in the systemic and molecular underpinnings of general anesthetic actions mediated by gamma-aminobutyric acid A receptors. Curr Opin Anaesthesiol. 2016;29(4):447\u201353.","journal-title":"Curr Opin Anaesthesiol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00801-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T03:51:37Z","timestamp":1610596297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00801-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"24 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethan Hoffmann, Amy Bullock, Abdul J. Sankoh, James Doherty, Stephen J. Kanes, and Helen Colquhoun are employees of Sage Therapeutics, Inc., with stock\/stock options. George G. Nomikos was formerly an employee of Sage Therapeutics, Inc., with stock\/stock options during the conduct of this study. He is currently in Clinical Development with Biogen, Inc. Inder Kaul is an employee of Kaul Consulting, LLC, which was contracted by Sage Therapeutics, Inc. for this study. Shane Raines is an employee of 2b Analytics, LLC, which was contracted by Sage Therapeutics, Inc. for this study. Jeff Wald is an employee of qPharmetra, LLC, which was contracted by Sage Therapeutics, Inc. for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}